99m Tc]Tc-MDP passing all standard, and above standard of care, quality assurance tests, which would normally be sufficient to allow human administration, there was altered biodistribution which could lead to erroneous clinical interpretation. The cause of the altered biodistribution remains unknown and requires further research.
Introduction
The majority of diagnostic nuclear medicine studies utilize 99m Tc as the base medical isotope. Until very recently over 70% of the world's supply of 99m Tc's parent isotope, 99 Mo, was produced as a fission product in two high enriched uranium (HEU) reactors, i.e., the National Research Universal (NRU) reactor at Chalk River, Canada and the high flux reactor (HFL) in the Netherlands [1, 2] .
Three major factors have catalyzed a search for alternate sources of 99 Mo/ 99m Tc. First, both the NRU and HFL reactors are over five decades old and both are nearing, and some would say beyond, their life expectancy. Second, in 2009/10 the world experienced a critical shortage of 99 Mo/ 99m Tc due to an unplanned shut down of the NRU reactor at the same time as planned maintenance down time of the HFL. This was a wakeup call to the world that the existing global production chain could not tolerate such perturbations in supply. Finally, and primarily for nuclear security reasons, the US Department of Energy's National Nuclear Security Administration has mandated a transition from HEU to low enriched uranium (LEU) 99 Mo/ 99m Tc production [1] [2] [3] [4] [5] [6] [7] . Alternate 99 Mo/ 99m Tc sources include: low enriched uranium fission products, neutron activation (i.e., 98 Mo(n, c) 99 Mo) , linear accelerator (e.g., 100 Mo(c, n) 99 Mo) and cyclotron (e.g., 100 Mo(p, 2n) 99m Tc) [8] [9] [10] . Research was conducted by the prairie isotope production enterprise (PIPE), in Winnipeg, Manitoba, Canada demonstrating proof of principle that neutron activated or LINAC produced 99 Mo could be utilized to extract [ 99m Tc]NaTcO 4 via liquid-liquid methyl ethyl ketone (MEK) extraction [11] . PIPE then conducted further research to demonstrate commercial viability relative to producing sufficient 99 Mo/ 99m Tc to meet clinical demands. This later research was to dovetail with a clinical trial. This paper focuses on the early unexpected results of the clinical trial.
Experimental

Radiochemistry
Procedures for the production of 99 Mo by nuclear reactorirradiation at the Missouri University research reactor (MURR, Columbia, MO) and [
99m Tc]NaTcO 4 solvent extraction have been previously described [12, 13] .
Quality control
The emphasis in this section will focus on the products used in the human clinical trial. For a detailed analysis of 99 Mo and 99m Tc quality assurance between MURR and commercial generator sources readers are referred to the article by Grigoryan et al. [11] . Radiochemical purity of labeled radiopharmaceutical was evaluated using instant thin layer chromatography (iTLC) strips from BIODEX Medical System Inc. (models 150-001 and 1500-005) with Acetone and distilled water as mobile phases. The pH of the tagged radiopharmaceutical was determined using the pH indicator test paper 4.0-7.0 (Merk) and validated with pH meter (Orion, Thermo Scientific).
Methods
Sterility
BacT Results for MURR sourced Pert used for the preparation of MDP samples utilized in clinical trials are summarized in Table 1 .
All radio-iTLC results were above the passing 90% limit, with the majority being well above 95%. Aside from two extractions which had pH values above passing specifications (Pert from these extractions were not used in the clinical trial), all others were within the USP range of 4.5-7.5. A trend of decreasing pH with subsequent extractions was observed and the same trend was observed in pertechnetate obtained from the commercial UltraTechnikov TM V4 generator (Mallinckrodt Pharmaceuticals). All MURR sourced Pert used for the clinical trial passed all quality assurance tests. 99 Mo breakthrough results for the MURR Pert were all within the passing specification of \ 0.15 kBq 99 Mo/MBq. Moly breakthrough was typically higher, but always within specification, for the first extraction of the generator and then decreases through subsequent extractions.
Germanium spectra of the pertechnetate obtained from commercial generator, Fig. 1a and MURR Pert, Fig. 1b , and show no significant observable differences. Both show main peak at 140 keV and summation peak of 280 keV, which corresponds to 99m Tc, with no other significant peaks (both samples immediately after extraction, i.e. 0 h).
All extractions of pertechnetate passed sterility and pyrogenicity tests.
Radiolabeling of MDP
A total of 21 preparations of MDP using MURR Pert were made which include the 4 radiolabeled products used in the clinical trial (Table 2) .
Passing specification for [ 99m Tc]Tc-MDP radio-iTLC is C 90%. The majority of the acetone and water radioiTLC results were [ 95% and were similar to results for radiolabeled MDP when pertechnetate from a commercial generator was used. All radiolabeled MDPs had the pH values within the passing specifications of 6-6.5.
Sterility and pyrogenicity
Each extraction of MURR Pert passed tests for sterility and pyrogenicity and all radiolabeled MDPs passed sterility tests.
Animal biodistribution study Animals were sacrificed at 10 min, 2, and 4 h post injection and dissected to measure the percent of total activity in each organ using a HIDEX Gamma counter. Biodistribution of the MDP is very similar between the two sets of radiopharmaceuticals (MURR and commerical or HSC). Both show a gradual uptake of MDP into the GI tract as time progresses; however with a relative trend of increasing large bowel uptake of MDP for the MURR MDP injected mice.
A two tail Students t test for independence was used to compare organ/tissue uptake at 10 min and 2 and 4 h after tail vein injection. Significant differences, at the p B 0.05 level, were generally scattered and inconsistent. Results are presented in Fig. 3 .
The MURR MDP had significantly decreased femur uptake at 10 min and 2 h but not at 4 h. MURR MDP had significantly increased spine uptake at 2 h but not at the other time points. Relative to the human imaging findings it is notable that the MURR product had significantly increased relative activity in the large intestine at both 2 and 4 h. [15, 16] ).
Clinical trial
A set of experienced Canadian Royal College of Physicians and Surgeons certified Nuclear Medicine physicians were to be presented with paired anterior and posterior whole body planar images labeled ''A'' and ''B'' representing the neutron activated and commercial generator sourced 99 Mo/ 99m Tc (randomly assigned to ''A'' or ''B''). The readers were to be presented only with the image data sets and were to be blinded as to the order of the paired images.
Imaging protocol
Tc-MDP) doses were 750 MBq (± 10%). Imaging parameters were the site's standard dual head whole body bone scan settings which were aligned between the standard of care and the investigational agent bone scans (e.g., specific gamma camera, time between injection and imaging acquisition settings). Two patients were imaged on a Siemens Symbia T6 and two on a GE Hawkeye Infinia systems.
Results
The trial was terminated after the first 4 patients were enrolled due to gross altered biodistribution between the two sets of images. This was noted by the study principal investigator when the image data sets were being prepared for the expert readers. These patients were recruited in a 2 week period and included the investigational agent from two separate neutron activated 99 Mo shipments. There were two females and two males recruited with an average b Fig. 1 Gamma-spectra of sodium pertechnetate extracted from: a A commercial Ultra-Technikov TM V4 generator (Mallinckrodt Pharmaceuticals) used in the Radiopharmacy department of Health Sciences. b The primary source 99 MoO 4 2-solution produced by dissolving nuclear reactor-irradiated sintered 99 Mo discs (MURR) After a chart review there were no protocol breaches for these participants, no significant interval interventions, no acute symptomatic episodes, and no known interfering medications to account for the findings.
To reiterate, and add to, the previous section, the MURR [ 99m Tc]Tc-MDP passed all quality control parameters including some beyond standard of care testing (e.g., radioiTLC (Pert and MDP), pH (Pert and MDP), Germanium spectroscopy (Pert), 99 Mo breakthrough, and mass spectroscopy (Pert).
Discussion
Elution of generator and radiolabeling of commercial MDP was performed by experienced technologists according to existing SOP's. Proper handling procedures were proven many times during regular Radiopharmacy production. Intervals between Pert elution were less than 24 h to minimize formation of 99 Tc (i.e., cold pert) that can compete with 99m Tc for stannous reduction and chelation reactions. All product used in the clinical trial were prepared as specified in the commercial MDP kit monograph.
Radiation can interact with water molecules forming ions, free radicals and peroxides particularly at higher activities and is well described [17] [18] [19] . Peroxides and hydroxyl free radicals are capable of oxidizing stannous ion and interact with technetium complexes to cause decomposition and oxidation of reduced technetium resulting in production of free Pert, noting that there was no evidence of free Pert on the study participants images. Peroxides tend to build up over time and may be present in the eluate from a generator with prolonged in-growth time, or Pert aged for several hours since elution. However, ascorbic acid that is present in the MDP kit should substantially reduce radiolytic decomposition.
Galea et al. [20] 
Conclusion
This study illustrates the importance of being vigilant and managing unexpected findings when conducting a clinical trial. Despite the investigational agent passing all standard, and above standard of care, quality assurance tests, which would normally be sufficient to allow human administration, there was altered biodistribution which could lead to erroneous clinical interpretation. The cause of the altered biodistribution remains unknown and requires further research. 
